389 related articles for article (PubMed ID: 25469140)
21. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Jakubowski JA; Li YG; Small DS; Payne CD; Tomlin ME; Luo J; Winters KJ
J Cardiovasc Pharmacol; 2010 Jul; 56(1):29-37. PubMed ID: 20386460
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Yokoi H; Kimura T; Isshiki T; Ogawa H; Ikeda Y
Thromb Res; 2012 May; 129(5):623-8. PubMed ID: 22178576
[TBL] [Abstract][Full Text] [Related]
24. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
25. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
26. High and low on-treatment platelet reactivity to P2Y
Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
[TBL] [Abstract][Full Text] [Related]
28. Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions.
Kumari P; Ranwa BL
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S319-S322. PubMed ID: 30595283
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic Assessment of Platelet Reactivity After a Loading Dose of Prasugrel or Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction.
Ichikawa S; Tsukahara K; Minamimoto Y; Kimura Y; Matsuzawa Y; Maejima N; Iwahashi N; Hibi K; Kosuge M; Ebina T; Kimura K
Circ J; 2016 Nov; 80(12):2520-2527. PubMed ID: 27725493
[TBL] [Abstract][Full Text] [Related]
30. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel.
Aradi D; Kuliczkowski W; Atar D; Serebruany VL
Thromb Haemost; 2012 Feb; 107(2):338-45. PubMed ID: 22186910
[TBL] [Abstract][Full Text] [Related]
31. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up.
Koziński M; Obońska K; Stankowska K; Navarese EP; Fabiszak T; Stolarek W; Kasprzak M; Siller-Matula JM; Rość D; Kubica J; De Servi S
Cardiol J; 2014; 21(5):547-56. PubMed ID: 24671900
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Li YG; Ni L; Brandt JT; Small DS; Payne CD; Ernest CS; Rohatagi S; Farid NA; Jakubowski JA; Winters KJ
Platelets; 2009 Aug; 20(5):316-27. PubMed ID: 19637095
[TBL] [Abstract][Full Text] [Related]
33. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis.
Ohno Y; Kitahara H; Fujii K; Kohno Y; Ariyoshi N; Nishi T; Fujimoto Y; Kobayashi Y
J Cardiol; 2019 Jan; 73(1):51-57. PubMed ID: 30055865
[TBL] [Abstract][Full Text] [Related]
34. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
35. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
[TBL] [Abstract][Full Text] [Related]
36. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Erlinge D; Ten Berg J; Foley D; Angiolillo DJ; Wagner H; Brown PB; Zhou C; Luo J; Jakubowski JA; Moser B; Small DS; Bergmeijer T; James S; Winters KJ
J Am Coll Cardiol; 2012 Nov; 60(20):2032-40. PubMed ID: 23083774
[TBL] [Abstract][Full Text] [Related]
37. Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions: The PRAISE study.
Guo LZ; Kim MH; Shin ES; Ann SH; De Jin C; Cho YR; Park JS; Park K; Park TH; Lee MS; Serebruany VL
Int J Cardiol; 2016 Nov; 222():639-644. PubMed ID: 27517654
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
39. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y
Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876
[TBL] [Abstract][Full Text] [Related]
40. Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation.
Tello-Montoliu A; Rivera J; Hernández D; Silvente A; Jover E; Rodriguez AI; Quintana M; Romero A; Orenes-Piñero E; Rivera-Caravaca JM; Marín F; Veliz A; Valdés M
Circ J; 2018 Jan; 82(2):353-360. PubMed ID: 28883222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
